


Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/751,274
				Filing Date	December 31, 2003
				First Named Inventor	KOZLOWSKI, Antoni
				Group Art Unit	1713
				Examiner Name	Robago, R.
Sheet	1	of	9	Attorney Docket Number	6800-0063

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
RM	A1	4,179,337	A	Davis, et al.	12-18-1979
	A2	4,179,551	A	Jones, et al.	12-18-1979
	A3	4,229,550	A	Jones, et al.	10-21-1980
	A4	4,251,626	A	Minamizono, et al.	02-17-1981
	A5	4,645,741	A	Inada	02-24-1987
	A6	4,675,414	A	Defusco, et al.	06-23-1987
	A7	4,839,345	A	Hiroshi, et al.	06-13-1989
	A8	5,166,322	A	Shaw, et al.	11-24-1992
	A9	5,527,528	A	Allen, et al.	06-18-1996
	A10	5,583,114	A	Barrows, et al.	12-10-1996
	A11	5,585,484	A	Acharya, et al.	12-17-1996
	A12	5,620,689	A	Allen, et al.	04-15-1997
	A13	5,641,856	A	Meurs, et al.	06-24-1997
	A14	5,766,897	A	Braxton	6-16-1998
	A15	5,844,020	A	Paine, et al.	12-01-1998
	A16	5,932,462	A	Harris, et al.	08-03-1999
	A17	6,001,958	A	Tapolsky, et al.	12-14-1999
	A18	6,139,819	A	Unger, et al.	10-31-2000
	A19	6,180,134	B1	Zalipsky, et al.	01-03-2001
	A20	6,180,598	B1	Nelson	01-30-2001
	A21	6,183,738	B1	Clarke	02-06-2001
	A22	6,210,707	B1	Papahadjopoulos, et al.	04-03-2001
	A23	6,261,537	B1	Klaveness, et al.	07-17-2001
	A24	6,271,339	B1	Thepot, et al.	08-07-2001
	A25	6,303,119	B1	Weisgerber, et al.	10-16-2001
	A26	6,306,923	B1	Thepot, et al.	10-23-2001
	A27	6,331,289	B1	Klaveness, et al.	12-18-2001
	A28	6,521,211	B1	Unger, et al.	02-18-2003
	A29	6,552,170	B1	Thompson, et al.	04-22-2003
	A30	6,602,498	B2	Shen, et al.	08-05-2003
	A31	2001/0044526	A1	Shen	11-22-2001
	A32	2002/0082345	A1	Kozlowski, et al.	06-27-2002
	A33	2003/0065134	A1	Sakanoue, et al.	04-03-2003
	A34	2003/0086867	A1	Lanza, et al.	05-08-2003
	A35	2003/0149307	A1	Hai, et al.	08-07-2003
	A36	2003/0162693	A1	Winslow, et al.	08-28-2003
	A37	2003/0170474	A1	Qiao, et al.	09-11-2003
	A38	2004/0167287	A1	Kozlowski, et al.	08-26-2004
RM	A39	2005/0014903	A1	Kozlowski, et al.	01-20-2005

Examiner Signature	<i>Robago</i>	Date Considered	3/17/06
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/751,274
				Filing Date	December 31, 2003
				First Named Inventor	KOZLOWSKI, Antoni
				Group Art Unit	1713
				Examiner Name	Robago, R.
Sheet	2	of	9	Attorney Docket Number	6800-0063

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ²
		Office ³	Number ⁴	Kind Code			
RM	B1	CN	1110681	A	Shanghai Biochemistry Inst.	10-25-1995	
	B2	DE	19652544	A1	Wacker-Chemie G.m.b.H.	06-18-1998	
	B3	EP	357110	A1	AKZO N.V.	03-07-1990	
	B4	EP	878482	A1	Dainippon Ink and Chemicals, Inc.	11-18-1998	
	B5	EP	0714402	B9	PolyMASC Pharmaceuticals	11-15-2000	
	B6	EP	1046394	A2	ImaRx Pharmaceutical Corp.	10-25-2000	
	B7	FR	2206317	A1	Institut Francais du Petrole	06-07-1974	
	B8	JP	50110491	A2	Furukawa Electric Co.	08-30-1975	
	B9	JP	57192418	A2	Mitsui Toatsu Chemicals, Inc.	11-26-1982	
	B10	JP	57205413	A2	Mitsui Toatsu Chemicals, Inc.	12-16-1982	
	B11	JP	58015515	A2	Mitsui Toatsu Chemicals, Inc.	01-28-1983	
	B12	JP	58040374	A2	Mitsui Toatsu Chemicals, Inc.	03-09-1983	
	B13	JP	63277619	A2	Nippon Oils & Fats Co., Ltd.	11-15-1988	
	B14	JP	63286445	A2	Bridgestone Corp.	11-24-1988	
	B15	JP	01062338	A2	Bridgestone Corp.	03-08-1989	
	B16	JP	01088129	A2	Nippon Oils & Fats Co., Ltd.	04-03-1989	
	B17	JP	02149335	A2	Nippon Oils & Fats Co., Ltd.	06-07-1990	
	B18	JP	07132685	A2	Fuji Photo Film Co., Ltd.	05-23-1995	
	B19	JP	08041195	A2	Nippon Oils & Fats Co., Ltd.	02-13-1996	
	B20	JP	08117586	A2	Nippon Oils & Fats Co., Ltd.	05-14-1996	
	B21	JP	11349877	A2	Tektronic, Inc.	12-21-1999	
	B22	JP	2000/144033	A2	Dainippon Ink and Chemicals, Inc.	05-26-2000	
	B23	JP	2000/143729	A2	Dainippon Ink and Chemicals, Inc.	05-26-2000	
	B24	JP	2000/144041	A2	Dainippon Ink and Chemicals, Inc.	05-26-2000	
	B25	JP	2000/306605	A2	Dainippon Ink and Chemicals, Inc.	11-02-2000	
	B26	JP	2000/319252	A2	Dainippon Ink and Chemicals, Inc.	11-21-2000	
	B27	JP	2001/172554	A2	Dainippon Ink and Chemicals, Inc.	06-26-2001	
	B28	JP	2001/294777	A2	Dainippon Ink and Chemicals, Inc.	10-23-2001	
	B29	JP	2001/322976	A2	Dainippon Ink and Chemicals, Inc.	11-20-2001	
	B30	JP	2002/121221	A2	Dainippon Ink and Chemicals, Inc.	04-23-2002	
	B31	JP	2002/265442	A2	Dainippon Ink and Chemicals, Inc.	09-18-2002	
	B32	JP	2002/265541	A2	Dainippon Ink and Chemicals, Inc.	09-18-2002	
	B33	JP	2003/040939	A2	Dainippon Ink and Chemicals, Inc.	02-13-2003	
	B34	JP	2003/221443	A2	Dainippon Ink and Chemicals, Inc.	08-05-2003	
	B35	JP	2003/241337	A2	Konishiroku Photo Ind.	08-27-2003	
	B36	WO	90/12874	A2	Genetics Inst.	11-01-1990	
	B37	WO	92/16221	A1	Synergen, Inc.	10-01-1992	
	B38	WO	94/21235	A1	Liposome Technology, Inc.	09-29-1994	
	B39	WO	94/21281	A1	Liposome Technology, Inc.	09-29-1994	
RM	B40	WO	95/11987	A1	Incyte Pharmaceuticals, Inc.	05-04-1995	

Examiner Signature		Date Considered	3/17/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/751,274
				Filing Date	December 31, 2003
				First Named Inventor	KOZLOWSKI, Antoni
				Group Art Unit	1713
				Examiner Name	Robago, R.
Sheet	3	of	9	Attorney Docket Number	6800-0063

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ³
		Office ⁶	Number ⁷	Kind Code			
RL	B41	WO	96/32841	A1	Burstein Laboratories, Inc.	10-24-1996	
	B42	WO	96/40285	A1	ImaRx Pharmaceutical Corp.	12-19-1996	
	B43	WO	98/02743	A1	Sensors Technology Co.	01-22-1998	
	B44	WO	98/11919	A2	Diagnocure, Inc.	03-26-1998	
	B45	WO	98/18500	A2	Nycomed Imaging AS	05-07-1998	
	B46	WO	98/22092	A1	Regents of the University of California	05-28-1998	
	B47	WO	98/30575	A1	Nexstar Pharmaceuticals, Inc.	07-16-1998	
	B48	WO	98/31383	A1	Pheonix Pharmacologies, Inc.	07-23-1998	
	B49	WO	99/03887	A1	Bolder Biotechnology, Inc.	01-28-1999	
	B50	WO	99/13919	A1	ImaRx Pharmaceutical Corp.	03-25-1999	
	B51	WO	99/48918	A1	The Proctor & Gamble Co.	09-30-1999	
	B52	WO	99/48928	A1	Sun Chemical Corp.	09-30-1999	
	B53	WO	99/55837	A2	Nycomed Imaging AS	11-04-1999	
	B54	WO	99/64460	A1	Celltech Therapeutics, Ltd.	12-16-1999	
	B55	WO	00/005582	A2	Burstein Laboratories, Inc.	02-03-2000	
	B56	WO	00/010974	A2	DSM N.V.	03-02-2000	
	B57	WO	00/016733	A2	The Proctor & Gamble Co.	03-30-2000	
	B58	WO	00/026256	A2	Centocor, Inc.	05-11-2000	
	B59	WO	00/045856	A2	ImaRx Pharmaceutical Corp.	08-10-2000	
	B60	WO	01/007484	A2	The Proctor & Gamble Co.	02-01-2001	
	B61	WO	01/007577	A2	The Proctor & Gamble Co.	02-01-2001	
	B62	WO	01/012154	A2	Celltech Chiroscience, Ltd.	02-22-2001	
	B63	WO	01/048052	A1	Kyowa Hakko Kogyo Co., Ltd.	07-05-2001	
	B64	WO	02/037850	A2	Dainippon Ink and Chemicals, Inc.	02-06-2002	
	B65	WO	02/025644	A1	Dainippon Ink and Chemicals, Inc.	03-28-2002	
	B66	WO	02/035636	A1	Dainippon Ink and Chemicals, Inc.	05-02-2002	
	B67	WO	02/036161	A2	ImaRx Therapeutics, Inc.	05-10-2002	
	B68	WO	02/060978	A1	Kyowa Hakko Kogyo Co., Ltd.	08-08-2002	
	B69	WO	02/076428	A1	Alza Corp.	10-03-2002	
	B70	WO	02/083067	A2	Cryolife, Inc.	10-24-2002	
	B71	WO	02/100343	A2	Mandelmed, Inc.	12-19-2002	
	B72	WO	03/028640	A2	Univ. Vanderbilt	04-10-2003	
	B73	WO	03/034995	A2	Scripps Research Institute	05-01-2003	
	B74	WO	03/047549	A2	Mitsubishi Chem. Corp.	06-12-2003	
	B75	WO	03/057134	A2	Amgen, Inc.	07-17-2003	
	B76	WO	03/059363	A1	Sangart, Inc.	07-24-2003	
	B77	WO	03/061577	A2	Biogen, Inc.	07-31-2003	
RL	B78	WO	03/064462	A1	Chugai Pharmaceutical Co., Ltd.	08-07-2003	

Examiner Signature	<i>Robert Robago</i>	Date Considered	3/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

⁶ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁷ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁸ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/751,274		
		Filing Date	December 31, 2003		
		First Named Inventor	KOZLOWSKI, Antoni		
		Group Art Unit	1713		
		Examiner Name	Robago, R.		
Sheet	4	of	9	Attorney Docket Number	6800-0063

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
<i>RM</i>	C1	ACEVEDO, <i>et al.</i> , "Synthesis and Characterization of Imide End-Capped Oligomers of Poly(diethyleneglycol Terephthalate)," <i>J. of Applied Polymer Sci.</i> <u>38</u> (9):1745-1759 (1989)	
	C2	ACEVEDO, <i>et al.</i> , "Kinetic Study Of The Crosslinking Reaction Of Flexible Bismaleimides," <i>Polymer</i> <u>31</u> (10):1955-1959 (1990)	
	C3	ACEVEDO, <i>et al.</i> , "Semi-Interpenetrating Polymer Networks Of Maleimide End-Capped Oligoesters," <i>Polymer</i> <u>32</u> (12):2210-2214 (1991)	
	C4	ALAM, <i>et al.</i> , "The Importance Of Being Knotted: Effects Of The C-Terminal Knot Structure On Enzymatic And Mechanical Properties Of Bovine Carbonic Anhydrase II," <i>FEBS Letters</i> <u>519</u> (1-3):35-40 (2002)	
	C5	ALLEN, <i>et al.</i> , "Use Of The Post-Insertion Method For The Formation Of Ligand-Coupled Liposomes," <i>Cellular & Molecular Biol. Letters</i> <u>7</u> (3):889-894 (2002)	
	C6	ANDREADIS, <i>et al.</i> , "Use Of Immobilized PCR Primers To Generate Covalently Immobilized Dnas For In Vitro Transcription/Translation Reactions," <i>Nucleic Acids Research</i> <u>28</u> (2):II-VIII (2000)	
	C7	BESTMAN-SMITH, <i>et al.</i> , "Sterically Stabilized Liposomes Bearing Anti-HLA-DR Antibodies For Targeting The Primary Cellular Reservoirs Of HIV-1," <i>Biochimica et Biophysica Acta</i> <u>1468</u> (1-2):161-174 (2000)	
	C8	BIENIARZ, <i>et al.</i> , "Extended Length Heterobifunctional Coupling Agents For Protein Conjugations," <i>Bioconjugate Chem.</i> <u>7</u> :88-95 (1996)	
	C9	BLESSING, <i>et al.</i> , "Different Strategies For Formation Of PEGylated EGF-Conjugated PEI/DNA Complexes For Targeted Gene Delivery," <i>Bioconjugate Chem.</i> <u>12</u> (4):529-537 (2001)	
	C10	CHIAN, <i>et al.</i> , "Synthesis Of Bismaleimide Resin Containing The Poly(Ethylene Glycol) Side Chain: Curing Behavior And Thermal Properties," <i>J. of Applied Polymer Sci.</i> <u>85</u> (14):2935-2945 (2002)	
	C11	CHAIN, <i>et al.</i> , "Mechanical Properties And Morphology Of Poly(Ethylene Glycol)-Side-Chain-Modified Bismaleimide Polymer," <i>J. of Applied Polymer Sci.</i> <u>86</u> (3):715-724 (2002)	
<i>RM</i>	C12	CHLUBA, <i>et al.</i> , "Enhancement Of Gene Delivery By An Analogue Of α -MSH In A Receptor-Independent Fashion," <i>Biochimica et Biophysica Acta</i> <u>1510</u> (1-2):198-208 (2001)	

Examiner Signature	<i>Robert Robago</i>	Date Considered	3/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/751,274		
		Filing Date	December 31, 2003		
		First Named Inventor	KOZLOWSKI, Antoni		
		Group Art Unit	1713		
		Examiner Name	Robago, R.		
Sheet	5	of	9	Attorney Docket Number	6800-0063

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
PC	C13	CHRISTAKOPOULOS, <i>et al.</i> , "Enhancement Of pH-Stability Of A Low Molecular Mass Endoglucanase From <i>Fusarium Oxysporum</i> By Protein Pegylation," <i>Carbohydrate Res.</i> <u>314</u> (1-2):95-99 (1998)	
	C14	DAUTY, <i>et al.</i> , "Intracellular Delivery Of Nanometric DNA Particles Via The Folate Receptor," <i>Bioconjugate Chem.</i> <u>13</u> (4):831-839 (2002)	
	C15	DERYCKE, <i>et al.</i> , "Transferrin-Mediated Targeting Of Hypericin Embedded In Sterically Stabilized PEG-Liposomes," <i>International J. of Oncology</i> <u>20</u> (1):181-187 (2002)	
	C16	DIX, <i>et al.</i> , "Chain Extension And Crosslinking Of Telechelic Oligomers-I. Michael Additions Of Bismines To Bismaleimides And Bis(Acetylene Ketones)," <i>Eur. Polym. J.</i> <u>31</u> (7):647-652 (1995)	
	C17	FLEINER, <i>et al.</i> , "Studies On Protein-Liposome Coupling Using Novel Thiol-Reactive Coupling Lipids: Influence Of Spacer Length And Polarity," <i>Bioconjugate Chem.</i> <u>12</u> (4):470-475 (2001)	
	C18	FLES, <i>et al.</i> , "Synthesis And Spectroscopic Evidence Of N-Arylmaleimides And N-Aryl-2,3-Dimethylmaleimides," <i>Croatica Chemica Acta</i> , <u>76</u> (1):69-74 (2003)	
	C19	GAGNÉ, "Targeted Delivery Of Indinavir To HIV-1 Primary Reservoirs With Immunoliposomes," <i>Biochimica et Biophysica Acta</i> , <u>1558</u> (2):198-210, (2002)	
	C20	GAIÑA, <i>et al.</i> , "Bismaleimide Resins Containing Urethanic Moieties," <i>J of Macromolecular Sci. - Pure and Appl. Chem.</i> <u>A34</u> (12):2435-2449 (1997)	
	C21	GHENEIM, <i>et al.</i> , "Diels-Alder Reactions With Novel Polymeric Dienes And Dienophiles: Synthesis Of Reversibly Cross-Linked Elastomers," <i>Macromolecules</i> <u>35</u> (19):7246-7253 (2002)	
	C22	GUSENS, <i>et al.</i> , "Targeting Of The Photocytotoxic Compound AIPcS4 To Hela Cells By Transferring Conjugate PEG-Liposomes," <i>Intern. J. of Cancer</i> <u>101</u> (1):78-85 (2002)	
	C23	GOODSON, <i>et al.</i> , "Site-Directed Pegylation Of Recombinant Interleukin-2 At Its Glycosylation Site," <i>Biotech.</i> <u>8</u> :343-346 (1990)	
PC	C24	HAI, <i>et al.</i> , "Synthesis Of Water-Soluble, Nonimmunogenic Polyamide Cross-Linking Agents," <i>Bioconjugate Chem.</i> <u>9</u> (6):645-654 (1998)	

Examiner Signature	<i>Robert Robago</i>	Date Considered	3/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	10/751,274
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	December 31, 2003
		First Named Inventor	KOZLOWSKI, Antoni
		Group Art Unit	1713
		Examiner Name	Robago, R.
Sheet	6	of	9
		Attorney Docket Number	6800-0063

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
PK	C25	HAI, <i>et al.</i> , "Polymerization Of Diaspirin Cross-Linked Hemoglobin (DCLHb) With Water-Soluble, Non-immunogenic Polyamide Cross-Linking Agents," <i>Bioconjugate Chem.</i> <u>10</u> (6):1013-1020 (1999)	
	C26	HEIMBUCH, <i>et al.</i> , "Composites Of Vinyl Polystyrylpyridine/Bismaleimide-Aliphatic Ether Copolymers," <i>SAMPE Quarterly</i> <u>20</u> (3):17-21 (1989)	
	C27	HILL, <i>et al.</i> , "Diels-Alder Bioconjugation Of Diene-Modified Oligonucleotides," <i>J. Org. Chem.</i> <u>66</u> (16):5352-5358 (2001)	
	C28	HUWYLER, <i>et al.</i> , "Bypassing Of P-glycoprotein Using Immunoliposomes," <i>J. of Drug Targeting</i> <u>10</u> (1):73-79 (2002)	
	C29	ISHIDA, <i>et al.</i> , "Targeted Delivery And Triggered Release Of Liposomal Doxorubicin Enhances Cytotoxicity Against Human B Lymphoma Cells," <i>Biochimica et Biophysica Acta</i> , <u>1515</u> (2):144-158, (2001)	
	C30	JUSZCZAK, <i>et al.</i> , "UV Resonance Raman Study Of β93-Modified Hemoglobin A: Chemical Modifier-Specific Effects And Added Influences Of Attached Poly(Ethylene Glycol)," <i>Biochemistry</i> <u>41</u> (1):376-385 (2002)	
	C31	KIRPOTIN <i>et al.</i> , "Sterically Stabilized Anti-HER2 Immunoliposomes : Design And Targeting To Human Breast Cancer Cells In Vitro," <i>Biochemistry</i> <u>36</u> (1):66-75 (1997)	
	C32	KIRCHMEIER, <i>et al.</i> , "Correlations Between The Rate Of Intracellular Release Of Endocytosed Liposomal Doxorubicin And Cytotoxicity As Determined By A New Assay," <i>J. of Liposome Res.</i> <u>11</u> (1):15-29 (2001)	
	C33	KLEY, <i>et al.</i> , "Synthesis Of Novel Thiol-Reactive Amphiphilic Lipids Based On Cholesterol For Protein-Liposome Coupling," <i>Monatshefte für Chemie</i> <u>129</u> (3):319-327 (1998)	
	C34	KOGAN, "The Synthesis Of Substituted Methoxy-Poly(Ethyleneglycol) Derivatives Suitable For Selective Protein Modification," <i>Synthetic Communications</i> <u>22</u> (16):2417-2424 (1992)	
	C35	KUEHNE, <i>et al.</i> , "Synthesis And Characterization Of Membrane-Active GALA-OKT9 Conjugates," <i>Bioconjugate Chemistry</i> <u>12</u> (5):742-749 (2001)	
PK	C36	KULLBERG, <i>et al.</i> , "Development Of EGF-Conjugated Liposomes For Targeted Delivery Of Boronated DNA-Binding Agents," <i>Bioconjugate Chem.</i> <u>13</u> (4):737-743 (2002)	

Examiner Signature	<i>Robert R. Robago</i>	Date Considered	3/17/06
---------------------------	-------------------------	------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/751,274		
		Filing Date	December 31, 2003		
		First Named Inventor	KOZLOWSKI, Antoni		
		Group Art Unit	1713		
		Examiner Name	Robago, R.		
Sheet	7	of	9	Attorney Docket Number	6800-0063

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
<i>RL</i>	C37	LEE, <i>et al.</i> , "A New Gene Delivery Formulation Of Polyethylenimine/DNA Complexes Coated With PEG Conjugated Fusogenic Peptide," <i>Journal of Controlled Release</i> <u>76</u> (1-2):183-192 (2001)	
	C38	LU, <i>et al.</i> , "Preparation And Biological Evaluation Of Polymerizable Antibody Fab' Fragment Targeted Polymeric Drug Delivery System," <i>Journal of Controlled Release</i> <u>74</u> (1-3):263-268 (2001)	
	C39	MAKMURA, <i>et al.</i> , "Development Of A Sensitive Assay To Detect Reversibly Oxidized Protein Cysteine Sulfhydryl Groups," <i>Antioxidants & Redox Signaling</i> <u>3</u> (6):1105-1118 (2001)	
	C40	MANJULA, <i>et al.</i> , "Cys-93-β-Succinimidophenyl Polyethylene Glycol 2000 Hemoglobin A. Intramolecular Cross-Bridging Of Hemoglobin Outside The Central Cavity," <i>The J. of Biological Chemistry</i> <u>275</u> (8):5527-5534 (2000)	
	C41	MANJULA, <i>et al.</i> , "Site-Specific PEGylation Of Hemoglobin At Cys-93(β): Correlation Between The Colligative Properties Of The PEGylated Protein And The Length Of The Conjugated PEG Chain," <i>Bioconjugate Chem.</i> <u>14</u> :464-472 (2003)	
	C42	MAO, <i>et al.</i> , "Chitosan-DNA Nanoparticles As Gene Carriers: Synthesis, Characterization And Transfection Efficiency," <i>J. of Controlled Release</i> <u>70</u> (3):399-421 (2001)	
	C43	MARUYAMA, <i>et al.</i> , "Targeting Efficiency Of PEG-Immunoliposome-Conjugated Antibodies At PEG Terminals," <i>Advaced Drug Delivery Reviews</i> <u>24</u> (2,3):235-242 (1997)	
	C44	MARUYAMA, <i>et al.</i> , "Targetability Of PEG-Immunoliposomes Conjugating Antibodies At The Ends Of PEG Chains," <i>Polymer Preprints</i> <u>38</u> (1):541-542 (1997)	
	C45	MENEZES, <i>et al.</i> , "Cellular Trafficking And Cytotoxicity Of Anti-CD19-Targeted Liposomal Doxorubicin In B Lymphoma Cells," <i>Journal of Liposome Research</i> <u>9</u> (2):199-228 (1999)	
	C46	MEYER, <i>et al.</i> , "Cationic Liposomes Coated With Polyethylene Glycol As Carriers For Oligonucleotides", <i>The J. of Biological Chemistry</i> , <u>273</u> (25):15621-15627 (1998)	
	C47	MOREIRA, <i>et al.</i> , "Targeting Stealth Liposomes In A Murine Model Of Human Small Cell Lung Cancer," <i>Biochimica et Biophysica Acta</i> <u>1515</u> (2):167-176 (2001)	
<i>RL</i>	C48	OLIVER, <i>et al.</i> , "Synthesis Of Pegylated Immunonanoparticles," <i>Pharmaceutical Res.</i> <u>19</u> (8):1137-1143 (2002)	

Examiner Signature	<i>Robert Robago</i>	Date Considered	3/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/751,274		
		Filing Date	December 31, 2003		
		First Named Inventor	KOZLOWSKI, Antoni		
		Group Art Unit	1713		
		Examiner Name	Robago, R.		
Sheet	8	of	9	Attorney Docket Number	6800-0063

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
PK	C49	PERRET, <i>et al.</i> , "Versatile Decoration Of Glass Surfaces To Probe Individual Protein-Protein Interactions And Cellular Adhesion," <i>Langmuir</i> <u>18</u> (3):846-854 (2002)	
	C50	Pierce Product Catalog "SMCC (Succinimidyl 4-[N-Maleimidomethyl]Cyclohexane-1-Carboxylate)," Product No. 22360 (2002)	
	C51	REDDY, <i>et al.</i> , "Folate-Targeted, Cationic Liposome-Mediated Gene Transfer Into Disseminated Peritoneal Tumors," <i>Gene Therapy</i> <u>9</u> (22):1542-1550 (2002)	
	C52	ROMANI, <i>et al.</i> , "Synthesis Of Unsymmetrical Cystine Peptides: Directed Disulfide Pairing With The Sulfenohydrazide Method," <i>Chem. of Peptides and Proteins</i> <u>2</u> :29-34 (1984)	
	C53	SAPRA, <i>et al.</i> , "Targeting Of Immunoliposomal Vincristine To Hematological Malignancies," <i>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater. Controlled Release Soc.</i> <u>28</u> :582-583 (2001)	
	C54	SAPRA, <i>et al.</i> , "Internalizing Antibodies Are Necessary For Improved Therapeutic Efficacy Of Antibody-Targeted Liposomal Drugs," <i>Cancer Res.</i> <u>62</u> (24):7190-7194 (2002)	
	C55	SCHMIDT, <i>et al.</i> , "Force Tolerances Of Hybrid Nanodevices," <i>Nano Letters</i> <u>2</u> (11):1229-1233 (2002)	
	C56	Shearwater Catalog, "Polyethelene Glycol And Derivatives For Biomedical Applications," Shearwater Corporation, pp. 1-17 (2001)	
	C57	SHI, <i>et al.</i> , "Noninvasive Gene Targeting To The Brain," <i>Proceed. Of the Nat'l Academy of Sci. of the U.S.A.</i> <u>97</u> (13):7567-7572 (2000)	
	C58	SHI, <i>et al.</i> , "Brain-Specific Expression Of An Exogenous Gene After I.V. Administration," <i>Proceed. Of the Nat'l Academy of Sci. of the U.S.A.</i> <u>98</u> (22):12754-12759 (2001)	
	C59	SHUKLA, <i>et al.</i> , "Synthesis And Biological Evaluation Of Folate Receptor-Targeted Boronated PAMAM Dendrimers As Potential Agents For Neutron Capture Therapy," <i>Bioconjugate Chem.</i> <u>14</u> (1):158-167 (2003)	
PK	C60	SOUZA, <i>et al.</i> , "Membrane-Active Properties Of α -MSH Analogs: Aggregation And Fusion Of Liposomes Triggered By Surface-Conjugated Peptides," <i>Biochimica et Biophysica Acta</i> <u>1558</u> (2):222-237 (2002)	

Examiner Signature	<i>Robert Robago</i>	Date Considered	3/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/751,274		
		Filing Date	December 31, 2003		
		First Named Inventor	KOZLOWSKI, Antoni		
		Group Art Unit	1713		
Examiner Name	Robago, R.				
Sheet	9	of	9	Attorney Docket Number	6800-0063


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
PK	C61	TAKIZAWA, <i>et al.</i> , "Targetability Of The Pendant Type Polyethyleneglycol-Immunoliposomes In Vivo," <i>Drug Delivery System</i> <u>13</u> (6):407-414 (1998)	
	C62	TANG, <i>et al.</i> , "Preparation Of A New Pegylation Reagent For Sulfhydryl-Containing Polypeptide," <i>Tetrahedron Letters</i> <u>35</u> (35):6515-6516 (1994)	
	C63	TESSMAR, <i>et al.</i> , "Amine-Reactive Biodegradable Diblock Copolymers", <i>Biomacromolecules</i> <u>3</u> (1):194-200 (2002)	
	C64	TSUTSUMI, <i>et al.</i> , "Site-Specific Chemical Modification With Polyethylene Glycol Of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) Improves Antitumor Activity And Reduces Animal Toxicity And Immunogenicity," <i>Proceed. of the Nat'l Academy of Sci. of the U.S.A.</i> <u>97</u> (15):8548-8553 (2000)	
	C65	TURNER, <i>et al.</i> , "The Transfection Of Jurkat T-Leukemic Cells By Use Of pH-Sensitive Immunoliposomes," <i>Journal of Liposome Research</i> <u>12</u> (4):311-334 (2002)	
	C66	VARGAS, <i>et al.</i> , "Diels-Alder Modification Of Poly(Ethylene Terphthalate-Co-Anthracene-2,6-Carboxylate) With N-Substituted Maleimides," <i>J. of Polymer Sci.</i> <u>40</u> (19):3256-3263 (2002)	
	C67	VREELAND, <i>et al.</i> , "Molar Mass Profiling Of Synthetic Polymers By Free-Solution Capillary Electrophoresis Of DNA-Polymer Conjugates," <i>Anal. Chem.</i> <u>73</u> (8):1795-1803, (2001)	
	C68	WU, <i>et al.</i> , "p53 Protein Oxidation In Cultured Cells In Response To Pyrrolidine Dithiocarbamate: A Novel Method For Relation The Amount Of p53 Oxidation In Vivo To The Regulation Of p53-Responsive Genes", <i>Biochem. J.</i> , <u>351</u> (1):87-93, (2000)	
PK	C69	WÜNSCH, <i>et al.</i> , "A New Method For The Selective Synthesis of Unsymmetrical Cystine Peptides," <i>Peptides; Proceedings of the 17th European Peptide Symposium</i> , pp. 183-188 (1982)	

Examiner Signature	<i>Roberto Robago</i>	Date Considered	3/17/06
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.



[illegible]

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

